Top 42 Brain Regeneration startups
Nov 14, 2025
Like
26
These startups develop new diagnostic methods and treatments for brain diseases and traumas. They also create brain regeneration technologies for brain dementia.
1
Country: USA | Funding: $451.4M
Neuronetics has pioneered and refined the NeuroStar TMS Therapy system. This non-invasive, non-systemic treatment for depression uses a highly focused, pulsed magnetic field to stimulate function in targeted brain regions. NeuroStar TMS Therapy is a safe and effective outpatient procedure, performed in a physician's office with each treatment lasting about 37 minutes daily for four to six weeks.
Neuronetics has pioneered and refined the NeuroStar TMS Therapy system. This non-invasive, non-systemic treatment for depression uses a highly focused, pulsed magnetic field to stimulate function in targeted brain regions. NeuroStar TMS Therapy is a safe and effective outpatient procedure, performed in a physician's office with each treatment lasting about 37 minutes daily for four to six weeks.
2
Country: USA | Funding: $1.1B
Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.
3
Country: USA | Funding: $614.6M
Neumora Therapeutics is pioneering a new era of precision medicines for Brain Diseases
Neumora Therapeutics is pioneering a new era of precision medicines for Brain Diseases
4
Country: USA | Funding: $487.2M
At Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the gut informs our brains about our well-being, metabolism, and nutritional state. The gut-brain axis—the communication highway between our gut and our brain—offers an unprecedented opportunity to access and influence brain centers involved in fundamental human processes. An understanding of the biology mediated by the gut and gut-brain circuits will change the way we think about food, nutrition, and human physiology.
At Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the gut informs our brains about our well-being, metabolism, and nutritional state. The gut-brain axis—the communication highway between our gut and our brain—offers an unprecedented opportunity to access and influence brain centers involved in fundamental human processes. An understanding of the biology mediated by the gut and gut-brain circuits will change the way we think about food, nutrition, and human physiology.
5
Country: USA | Funding: $448.5M
Amylyx Pharmaceutical is a pharmaceutical company that specializes in providing solutions on Alzheimer’s and other diseases of the brain.
Amylyx Pharmaceutical is a pharmaceutical company that specializes in providing solutions on Alzheimer’s and other diseases of the brain.
6
Country: USA | Funding: $374M
Voyager Therapeutics is a clinical stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS). Gene therapy has the potential to transform the treatment of CNS and other diseases by providing a one-time therapy that dramatically improves patients' lives.
Voyager Therapeutics is a clinical stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS). Gene therapy has the potential to transform the treatment of CNS and other diseases by providing a one-time therapy that dramatically improves patients' lives.
7
Country: USA | Funding: $366.2M
Alzheon is committed to developing innovative medicines for patients suffering from Alzheimer's disease and other neurological and psychiatric disorders. Our Alzheon’s drug development platform which comprises proprietary chemistries, robust clinical efficacy and safety datasets in patients and genetically-defined subpopulations, and the ability to optimize molecules to have the desired therapeutic attributes.
Alzheon is committed to developing innovative medicines for patients suffering from Alzheimer's disease and other neurological and psychiatric disorders. Our Alzheon’s drug development platform which comprises proprietary chemistries, robust clinical efficacy and safety datasets in patients and genetically-defined subpopulations, and the ability to optimize molecules to have the desired therapeutic attributes.
8
Country: USA | Funding: $319.5M
Alector is a hypothesis-driven, neurology-focused startup that’s pioneering the discovery and development of first-in-class, immuno-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders. We are combining state-of-the-art antibody technology and recent discoveries in neuro-immunology and human genetics to develop a broad platform of novel therapeutics that harness the immune system to fight dementia and neurodegeneration.
Alector is a hypothesis-driven, neurology-focused startup that’s pioneering the discovery and development of first-in-class, immuno-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders. We are combining state-of-the-art antibody technology and recent discoveries in neuro-immunology and human genetics to develop a broad platform of novel therapeutics that harness the immune system to fight dementia and neurodegeneration.
9
Country: USA | Funding: $273.9M
Aptinyx Inc. is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication.
Aptinyx Inc. is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication.
10
Country: USA | Funding: $247M
Quince Therapeutics is developing novel treatments for altering the course of Alzheimer's and other degenerative diseases.
Quince Therapeutics is developing novel treatments for altering the course of Alzheimer's and other degenerative diseases.
11
Country: Canada | Funding: $225M
BlueRock Therapeutics is pioneering cell therapies that replace dead, damaged, or dysfunctional cells to restore critical natural functions in the body. The company is initially targeting severe brain and heart conditions, two areas of critical unmet medical need with blockbuster potential.
BlueRock Therapeutics is pioneering cell therapies that replace dead, damaged, or dysfunctional cells to restore critical natural functions in the body. The company is initially targeting severe brain and heart conditions, two areas of critical unmet medical need with blockbuster potential.
12
Country: USA | Funding: $221M
Engrail Therapeutics is a developer of medicines to transform the lives of patients with life-limiting diseases of the nervous system.
Engrail Therapeutics is a developer of medicines to transform the lives of patients with life-limiting diseases of the nervous system.
13
Country: USA | Funding: $207M
Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing our proprietary RNA interference platform.
Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing our proprietary RNA interference platform.
14
Country: USA | Funding: $140M
Capsida develops targeted gene therapies in serious neurodegenerative diseases.
Capsida develops targeted gene therapies in serious neurodegenerative diseases.
15
Country: USA | Funding: $134.1M
We use genomic data to find better drugs, faster. We find new cures for brain diseases 1000X more cheaply and quickly using our proven network algorithms.
We use genomic data to find better drugs, faster. We find new cures for brain diseases 1000X more cheaply and quickly using our proven network algorithms.
16
Country: USA | Funding: $133.8M
Navidea Biopharmaceuticals has established a niche in precision medicine. The company focuses on the development and commercialization of diagnostic agents and therapeutics for cancer, autoimmune diseases, dementia, and movement disorders.
Navidea Biopharmaceuticals has established a niche in precision medicine. The company focuses on the development and commercialization of diagnostic agents and therapeutics for cancer, autoimmune diseases, dementia, and movement disorders.
17
Country: Israel | Funding: $85.5M
Brainsway has revolutionized brain disorder treatment, with Brainsway Deep TMS therapy, or Deep Transcranial Magnetic Stimulation. With Brainsway Deep TMS, patients can regain wellbeing, calm and happiness in just a few weeks.
Brainsway has revolutionized brain disorder treatment, with Brainsway Deep TMS therapy, or Deep Transcranial Magnetic Stimulation. With Brainsway Deep TMS, patients can regain wellbeing, calm and happiness in just a few weeks.
18
Country: Denmark | Funding: $77.9M
Muna develops transformative therapeutics to preserve brain function and enhance resilience to neurodegenerative diseases
Muna develops transformative therapeutics to preserve brain function and enhance resilience to neurodegenerative diseases
19
Country: Israel | Funding: $63.1M
BrainStorm Cell Therapeutics is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).
BrainStorm Cell Therapeutics is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).
20
Country: USA | Funding: $52.5M
Rune Labs is a software and data platform for neuromodulation and brain therapies of the future.
Rune Labs is a software and data platform for neuromodulation and brain therapies of the future.
